ArticleCureus2026
From Granulomas to Malignancy: Validating the Sydney System in a Tuberculosis-Endemic Landscape.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Sydney System for reporting lymph node cytopathology standardizes lymph node fine-needle aspiration cytology (FNAC) reporting and improves risk-based clinical stratification. Validation data from tuberculosis (TB)-endemic regions remain limited. MATERIALS AND
methodsThis retrospective observational multicentric study analyzed 427 consecutive lymph node FNAC cases from two tertiary care centers in Eastern India during January-December 2025. Three independent pathologists, reviewing slides at separate time points, categorized aspirates according to the Sydney System (L1-L5), blinded to clinical details and to each other's assignments. Histopathology and Ziehl-Neelsen staining served as reference standards. Diagnostic accuracy parameters with 95% confidence intervals (Wilson score method), receiver operating characteristic (ROC) analysis, category-wise risk of malignancy (ROM), TB correlation with a complete 2 × 2 matrix, and interobserver agreement (Cohen's kappa) were assessed.
resultsCervical lymph nodes constituted 357 (83.6%) cases. Reactive, granulomatous, and necrotizing lymphadenitis accounted for the majority of diagnoses; malignant lesions accounted for 39 cases (9.1%). The L2 (benign/reactive) category constituted the overwhelming majority of cases, with a mean of 384 (89.9%) across pathologists out of 427 cases. Per-pathologist sensitivity ranged from 79.5% to 84.6%; specificity was 99.7% across all three observers; positive predictive value was 96.9-97.1%; negative predictive value was 98.0-98.5%; and overall accuracy was 97.9-98.4%. ROC analysis demonstrated excellent discriminatory performance (AUC range: 0.935-0.974). ROM increased progressively from L2 to L5. Interobserver agreement was substantial to almost perfect (κ = 0.79-0.87). Among L2 cases, the sensitivity for TB capture was 98.6%; however, the PPV of L2 for TB was only 19.2%, and specificity was 13.0%, with 307 (80.8%) cases of granulomatous L2 findings attributable to non-TB aetiologies.
conclusionsThe Sydney System demonstrates excellent diagnostic accuracy, reproducibility, and clinically meaningful ROM stratification in a TB-endemic setting. Granulomatous cytomorphology alone is insufficient for TB diagnosis; microbiological confirmation is mandatory before assigning an L2 classification to TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.